While no universal threshold for cost-effectiveness exists, a cost per additional life-year gained or quality-adjusted life-year (QALY) in the range of EUR 25,000 (USD 33,000) to EUR 38,000 (USD 50,000) is generally considered as cost-effective [ 46, 47].
Cost effectiveness outcomes exist for other HIV-related programming, representing a wide array of interventions, including treatment, prevention and palliative care.
Lastly, because no official cost-effectiveness threshold exists in the Netherlands, it is difficult to state whether or not a new therapy will be considered cost effective.
Few well conducted cost-effectiveness studies exist that can be used to guide decision makers in the field of chronic wounds when the intervention is strategic in nature or is based on guidelines.
Few well conducted cost-effectiveness studies exist to guide decision makers regarding guideline-based or strategic interventions for chronic wounds.
Results confirm that a trade-off exists between cost, effectiveness and non-health arguments when respondents prioritise health programs.
To our knowledge, there exists no cost effectiveness model for the German setting yet, which compares mesalazines in the treatment of UC.
Our findings therefore confirm that a trade-off exists between cost, effectiveness and non-health arguments, despite the potential for uncontrolled interactions between health and non-health arguments.
15 20 In addition, no data exists on the cost effectiveness of preoperative skin antisepsis.
11 Since the estimation that the medical cost for a type 2 diabetes patient is two to four times greater than that for a patient without diabetes, 14 some evidence exists regarding the cost effectiveness of bariatric-metabolic surgery in the treatment of type 2 diabetes mellitus.
